-
Long-Acting Inhalable Drugs for Chronic Obstructive Pulmonary Disease
This study will describe the utilization of long-acting inhaled therapies for COPD in 6 provinces between 2012 and 2024, describing the characteristics of patients at treatment initiation and how treatment evolves over time.
HC0086Isotretinoin, Contraception, and Pregnancy Outcomes
This project is a replication of our previous study. The main objective is to update information on contraception use, pregnancy occurrence, and pregnancy outcomes during isotretinoin therapy.
OS0015Utilization of Antidiabetic Drugs During Pregnancy: A CDM Pilot Project
The objective of this pilot project is to determine the utilization of antidiabetic drugs among pregnant people living in Canada using CNODES' adaptation of the Sentinel Common Data Model.
HC0083_OS007_CDMAssociation Between Opioid Use and the Development of Diverticulitis
Opioid use is a potential risk factor for diverticulitis. However, evidence on the association between opioid analgesics and diverticulitis is limited. The overall aim of this study is to evaluate the feasibility of, and subsequently conduct, an observational study evaluating whether short-term and sustained opioid use are associated with elevated risks of diverticulitis in patients indicated for treatment with opioids.
OS0001Utilization of Potentially Inappropriate Medications in Patients with Major Neurocognitive Disorders
This study is a replication of the drug utilization study conducted by INESSS using data from Quebec to gather data from 6 additional provinces. The objectives are to identify incident and prevalent cases of major neurocognitive disorder among older adults and describe their characteristics and a set of indicators of the use of potentially inappropriate medications. The results from the Quebec study will be included into the overall findings.
HC0099Use of Oral Fluoroquinolones in Canada: A Drug Utilization Study Update
We will update our previous study to describe fluoroquinolone utilization trends from 2008 to 2022 and to assess the impact of the risk minimization measures introduced by Health Canada in 2017.